Literature DB >> 24985688

Robustness of automated hippocampal volumetry across magnetic resonance field strengths and repeat images.

Robin Wolz1, Adam J Schwarz2, Peng Yu2, Patricia E Cole2, Daniel Rueckert3, Clifford R Jack4, David Raunig5, Derek Hill6.   

Abstract

BACKGROUND: Low HCV has recently been qualified by the European Medicines Agency as a biomarker for enrichment of clinical trials in predementia stages of Alzheimer's disease. For automated methods to meet the necessary regulatory requirements, it is essential they be standardized and their performance be well characterized.
METHODS: The within-image and between-field strength reproducibility of automated hippocampal volumetry using the Learning Embeddings for Atlas Propagation (or LEAP) algorithm was assessed on 153 Alzheimer's Disease Neuroimaging Initiative subjects.
RESULTS: Tests/retests at 1.5 T and 3 T, and a comparison between 1.5 T and 3 T, yielded average unsigned variabilities in HCVs of 1.51%, 1.52%, and 2.68%. A small bias between field strengths (mean signed difference, 1.17%; standard deviation, 3.07%) was observed.
CONCLUSIONS: The measured reproducibility characteristics confirm the suitability of using automated magnetic resonance imaging analyses to assess HCVs quantitatively and to represent a fundamental characterization that is critical to meet the regulatory requirements for using hippocampal volumetry in clinical trials and health care.
Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Clinical trials; Hippocampus; Reproducibility; Segmentation; Test/retest

Mesh:

Year:  2014        PMID: 24985688     DOI: 10.1016/j.jalz.2013.09.014

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  17 in total

1.  Metric Learning for Multi-atlas based Segmentation of Hippocampus.

Authors:  Hancan Zhu; Hewei Cheng; Xuesong Yang; Yong Fan
Journal:  Neuroinformatics       Date:  2017-01

Review 2.  Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Michael C Donohue; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Paul M Thompson; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

3.  Diagnostic performance of hippocampal volumetry in Alzheimer's disease or mild cognitive impairment: a meta-analysis.

Authors:  Ho Young Park; Chong Hyun Suh; Hwon Heo; Woo Hyun Shim; Sang Joon Kim
Journal:  Eur Radiol       Date:  2022-05-04       Impact factor: 7.034

4.  Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.

Authors:  Peng Yu; Jia Sun; Robin Wolz; Diane Stephenson; James Brewer; Nick C Fox; Patricia E Cole; Clifford R Jack; Derek L G Hill; Adam J Schwarz
Journal:  Neurobiol Aging       Date:  2013-10-03       Impact factor: 4.673

5.  Power estimation for non-standardized multisite studies.

Authors:  Anisha Keshavan; Friedemann Paul; Mona K Beyer; Alyssa H Zhu; Nico Papinutto; Russell T Shinohara; William Stern; Michael Amann; Rohit Bakshi; Antje Bischof; Alessandro Carriero; Manuel Comabella; Jason C Crane; Sandra D'Alfonso; Philippe Demaerel; Benedicte Dubois; Massimo Filippi; Vinzenz Fleischer; Bertrand Fontaine; Laura Gaetano; An Goris; Christiane Graetz; Adriane Gröger; Sergiu Groppa; David A Hafler; Hanne F Harbo; Bernhard Hemmer; Kesshi Jordan; Ludwig Kappos; Gina Kirkish; Sara Llufriu; Stefano Magon; Filippo Martinelli-Boneschi; Jacob L McCauley; Xavier Montalban; Mark Mühlau; Daniel Pelletier; Pradip M Pattany; Margaret Pericak-Vance; Isabelle Cournu-Rebeix; Maria A Rocca; Alex Rovira; Regina Schlaeger; Albert Saiz; Till Sprenger; Alessandro Stecco; Bernard M J Uitdehaag; Pablo Villoslada; Mike P Wattjes; Howard Weiner; Jens Wuerfel; Claus Zimmer; Frauke Zipp; Stephen L Hauser; Jorge R Oksenberg; Roland G Henry
Journal:  Neuroimage       Date:  2016-04-01       Impact factor: 6.556

6.  Feasibility of the Medial Temporal lobe Atrophy index (MTAi) and derived methods for measuring atrophy of the medial temporal lobe.

Authors:  Francisco Conejo Bayón; Jesús Maese; Aníbal Fernandez Oliveira; Tamara Mesas; Estibaliz Herrera de la Llave; Tania Alvarez Avellón; Manuel Menéndez-González
Journal:  Front Aging Neurosci       Date:  2014-11-05       Impact factor: 5.750

7.  The Cognition and Affect after Stroke - a Prospective Evaluation of Risks (CASPER) study: rationale and design.

Authors:  Elles Douven; Syenna H J Schievink; Frans R J Verhey; Robert J van Oostenbrugge; Pauline Aalten; Julie Staals; Sebastian Köhler
Journal:  BMC Neurol       Date:  2016-05-12       Impact factor: 2.474

8.  Asymmetry of Hippocampus and Amygdala Defect in Subjective Cognitive Decline Among the Community Dwelling Chinese.

Authors:  Ling Yue; Tao Wang; Jingyi Wang; Guanjun Li; Jinghua Wang; Xia Li; Wei Li; Mingxing Hu; Shifu Xiao
Journal:  Front Psychiatry       Date:  2018-06-11       Impact factor: 4.157

9.  Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration.

Authors:  Robin Wolz; Adam J Schwarz; Katherine R Gray; Peng Yu; Derek L G Hill
Journal:  Neurology       Date:  2016-08-24       Impact factor: 9.910

Review 10.  Secondary prevention of Alzheimer's dementia: neuroimaging contributions.

Authors:  Mara Ten Kate; Silvia Ingala; Adam J Schwarz; Nick C Fox; Gaël Chételat; Bart N M van Berckel; Michael Ewers; Christopher Foley; Juan Domingo Gispert; Derek Hill; Michael C Irizarry; Adriaan A Lammertsma; José Luis Molinuevo; Craig Ritchie; Philip Scheltens; Mark E Schmidt; Pieter Jelle Visser; Adam Waldman; Joanna Wardlaw; Sven Haller; Frederik Barkhof
Journal:  Alzheimers Res Ther       Date:  2018-10-30       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.